S. AMH in PCOS Research Insights beyond a Diagnostic Marker

Similar documents
Antim ullerian hormone and polycystic ovary syndrome

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour

Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

PCOS and Obesity DUB is better treated by OCPs

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Polycystic Ovary Syndrome (PCOS):

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

Role of inositol in Reproductive Function

JMSCR Vol 05 Issue 05 Page May 2017

PCOS What s new in Diagnosis & Treatment?

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)

Polycystic Ovary Syndrome

Reproduction. AMH Anti-Müllerian Hormone. Analyte Information

Abnormal Uterine Bleeding Case Studies

Overview of Reproductive Endocrinology

New PCOS guidelines: What s relevant to general practice

Polycystic Ovarian Syndrome (PCOS) LOGO

Polycystic Ovary Syndrome

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page

Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

JMSCR Vol 06 Issue 09 Page September 2018

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Reproductive outcome in women with body weight disturbances

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

PCOS guidelines: What s relevant to general practice

Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG

Amenorrhoea: polycystic ovary syndrome

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women

Reproductive FSH. Analyte Information

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

Polycystic Ovarian Syndrome and Obstructive Sleep Apnea: Poor Bedpartners. M. Begay, MD UNM Sleep Medicine Fellow 01/31/2017

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Achieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Thesis. Mahmoud Sedki Yassin (MsC) Cairo University. Under supervision of


Diagnosis and Management of Polycystic Ovary Syndrome During Adolescence: Questions and Controversies

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

Prognosticating ovarian reserve by the new ovarian response prediction index

Is it the seed or the soil? Arthur Leader, MD, FRCSC

Insulin sensitizers in PCOS syndrome

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

Ontogeny of the new hypo-androgenic PCOS phenotype

Metabolic changes in menopausal transition

Polycystic ovary syndrome in young women - new ideas

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Selection criteria of normal controls to predict reliable cut-off values of various endocrine parameters in infertility

Phenotypes in Male & Female First Degree Relatives of Women with PCOS. Andrea Dunaif, MD

A Tale of Three Hormones: hcg, Progesterone and AMH

original article INTRODUCTION Since the introduction of anti-müllerian hormone ABSTRACT

Reproductive Health and Pituitary Disease

EXCEPTIONAL DIAGNOSTICS FOR REPRODUCTIVE DISEASE STATE MANAGEMENT. Anti-Müllerian Hormone (AMH)

Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS

Visceral adiposity index among young girls with PCOS and its association with phenotypes and metabolic risk


Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value

Clinical Manifestations of the Polycystic Ovary Syndrome at Menopausal Age

The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study

Association between Anti-Mullerian Hormone and Ovarian Response and Pregnancy in Polycystic Ovary Syndrome Patients

DOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS

New technology and criteria for PCOS and PCOM

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

(Predictive. value) Soheila Ansaripour Fellowship of infertility Ai Avicena Research In

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

Anti-Mullerian hormone (AMH) as predictor of ovarian reserve

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Infertility: A Generalist s Perspective

Editorial 2. Polycystic Ovary Syndrome: From in utero to Menopause INTRODUCTION GENETICS OF PCOS IN UTERO FETAL PROGRAMMING

PCOS-Understanding the Science and Practice. Inositols. Maurizio Nordio, University Sapienza, Rome, Italy Mumbai, June 18th, 2016

Clinical Profile Polycystic Ovarian Syndrome Cases

Assisted Reproductive. Technologies: Present and. Future

Polycystic Ovary Syndrome

WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH

AMH CUT-OFF VALUES FOR PREDICTING OVARIAN RESPONSE IN IVF. Nguyễn Xuân Hợi, MD, PhD Hoàng Văn Hùng MsC, MD

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

Evaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis

Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.

Female Reproductive Endocrinology

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome

Approach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD

A Tale of Three Hormones: hcg, Progesterone and AMH

Chapter 16 Polycystic Ovary Syndrome in Adolescent Girls

Why Do We Treat Obesity? Organ-Specific, Hormonal, and Biomechanical Complications

Infertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations

LH activity administration during the

Transcription:

S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr. Anushree Patil, Dr. Shahina Begum, Dr. Beena Joshi)

Multidisciplinary PCOS Clinic at NIRRH Gynaecologist Consultation Community Activities Counseling on Nutrition and PCOS Yoga Session

Anti Mullerian Hormone Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein linked by disulfide bonds and a molecular weight of 140kDa. The hormone belongs to the Transforming Growth Factor-β (TGF-β) superfamily The gene encoding AMH is located in the short arm of chromosome 19 AMH plays an important role in male sex differentiation as its production by the embryonic testes induces the regression of Mullerian ducts AMH action is exerted through two receptors: type I receptor (AMHRI) and type II receptor (AMHRII) which are present on the AMH target-organs (gonads and Mullerιan ducts)

Specific Actions of AMH in Human Ovary AMH is produced by the granulosa cells of small growing follicles In female neonates, AMH is virtually undetectable but increases gradually until puberty and remains relatively stable thereafter and throughout the reproductive period Inhibits initial follicle recruitment Inhibits FSH-dependent growth and selection of pre antral and small antral follicles. AMH remains highly expressed in cumulus cells of mature follicles. AMH has inhibitory effect on FSH-induced CYP19a1 expression leading to reduced estradiol (E2) levels Dewailly, D., et al., Hum Reprod Update, 2014

Two Cell Two Gonadotropin Theory

AMH: Clinical Utility Diagnostic Marker Ovarian Reserve Predictive Marker For OHSS Tumor Marker For Granulosa Cell Tumors Interpretation AMH Range (ng/ml) High Above 4.0 Normal 1.5-4.0 Low Normal 1.0-1.5 Low 0.5-1.0 Prognostic Marker For predicting ovarian response in COH Upcoming Diagnostic Marker For PCOS Follicular Fluid Levels Correlate with Pregnancy rate

AMH in PCOS AMH production in PCOS granulosa cells is increased by 75%* AMH excess has an essential role in the process of follicular arrest AMH may be used as a marker of ovarian follicle impairment in PCOS Serum and follicular AMH levels are higher in PCOS ** Serum AMH values could be useful particularly in cases in which the transvaginal ultrasound examination is not feasible *** Though values are higher in adolescents, not a predictor of PCOS Age related decline has slower reduction rate of s. AMH Levels lower in obese women with PCOS *Pellat et al.; 2007. J Clin Endocrinol Metab 2007 **Fallat ME et al.; Fertil Steril 1997 ***Pigny P et al.; J Clin Endocrinol Metab 2006

AMH in PCOS AMH independently and positively correlated with LH, testosterone, androstendione and free androgen index (FAI) values and the number of small follicles* Differences in AMH concentrations between four phenotypic groups of PCOS reflected the severity of the syndrome A correlation between AMH levels and HOMA-IR values has not been confirmed in studies Significant positive correlation between AMH levels and AGEs in normal weight women with PCOS ** * Laven JS et al.; J Clin Endocrinol Metab 2004 **Diamanti-Kandarakis E et al.; Eur J Endocrinol 2009

Objective To study the correlation of AMH among PCOS women with Hormonal profile Biochemical parameters Anthropometric measurements Body mass composition

Materials and Methods Study design: Clinic based observational cross sectional study Study sites: NIRRH Multidisciplinary PCOS Clinic Study Population: Women diagnosed with PCOS using Rotterdam criteria Selection Criteria Inclusion criteria (2 out of 3) Anovulation Hyperandrogenism, clinical or biochemical USG evidence of PCO Exclusion criteria Not willing for blood collection On oral contraceptive pills Study Duration: One Year

Investigations Hormonal Biochemical Ultrasound FSH FBS USG pelvis for PCOS and endometrial thickness LH PGBS (post 75g) USG abdomen for Non Alcoholic Fatty Hormonal Liver (NAFL) and cholelithiasis TSH, Free T4 PRL Lipid profile S. Testosterone Calcium SHBG LFT (only in NAFLD) Hb CBC (routine) 17-OHP Insulin fasting Insulin post glucose 25(OH)D AMH CRP Free Androgen Index & HOMAIR were calculated

Percent PCOS: NIRRH Data 70 60 50 40 30 20 10 0 64 PCOS at NIRRH Infertility Clinic (n=383) 9.92 6 4 4 6 6 6.53 Body Mass Index (n=100 PCOS Women) Waist Hip Ratio (n=100 PCOS women) 60 55.2 More than 0.8 less than 0.8 50 40 less than 0.8, 30% 30 27 20 10 0 6.3 11.6 < 19 19.1-23 23.1-24.9 Obese 25 and above More than 0.8, 70%

Mean Age Hormonal and Biochemical parameters (n=55) Mean (±SD) Age 26.33 years 5.088 LH 10.28 miu /ml 6.28 FSH 06.63 miu /ml 1.34 S. Testosterone 50.77 ng/dl 20.33 SHBG 33.63 nmol/ 18.02 FAI 06.59 04.45 HOMAIR 04.13 02.25 25(OH)D 12.77 ng/ml 07.96 AMH 07.96 ng/ml 04.70

AMH value Correlation between AMH and Age Age Group n Mean AMH (±SD) 15-20 8 9.1 (5.4) 20-30 37 8.4 (4.8) 30-40 17 6.5 (4.8) No significant difference was found in mean AMH levels among age groups ANOVA, p= 0.35 20 18 16 14 12 10 8 6 4 2 0 10 15 20 25 30 35 40 Age Inverse relationship between age and AMH Correlation (r)= -0.14, p=0.27

Cut off Values of AMH for Diagnosis of PCOS Author Year Cut off level pmol/ml Sensitivity (%) Specificity (%) Iliodromiti 2016 33.6 82 79 Saikumar 2013 23.8 98 93 Casadei 2013 33 95 95 Dewailley 2011 35.7 92 97

Correlation of AMH with Anthropometry and Body Mass Composition Parameter Mean SD r p Waist Circumference Hip Circumference 88.69 12.51-0.21 0.11 101.71 11.44-0.12 0.36 Waist: Hip ratio 0.86 0.12-0.15 0.28 Total fat% 34.7 4.70-0.21 0.15 Visceral fat % 8.87 6.64-0.14 0.92 Skeletal Muscle % 23.7 1.9 0.18 0.2 BMR 1288 177.41-0.20 0.16

AMH value Correlation between AMH and BMI BMI Category n Mean AMH (SD) <18 Underweight 1 6 18-23 Normal 13 9.9 (5.2) 23-25 Overweight 7 10.2 (5.3) >25 Obese 34 7.2 (3.9) 20 18 16 14 12 10 8 6 4 2 0 10 15 20 25 30 35 40 45 BMI r= -0.23, p=0.09 Difference was not statistically significant with BMI

Correlation of AMH with Hormonal Biochemical Parameters Variable r p value LH 268 0.03* FSH -0.14 0.24 s. Testosterone 0.28 0.02* SHBG 0.8 0.52 FAI 0.147 0.293 HOMAIR -0.33 0.016* 25(OH)D 0.265 0.03* Pearson Correlation applied

S. AMH and HOMAIR Category of Insulin Resistance Normal IR Moderate IR HOMAIR n % Mean AMH ng/ml SD <3 17 30.9 8.6 3.45 3-5 25 45.5 9.66 5.37 Severe IR >5 13 23.6 5.11 2.09

Limitations Small sample size Comparison with healthy controls required

Results Inverse correlation with age Positive correlation with LH and s. Testosterone Negative correlation with HOMAIR Conclusion Beyond a diagnostic marker, AMH may have a significant role in the hyperandrogenemia of PCOS

Clinical Implication: Monitoring Treatment Response Contraceptives containing 35mg of ethynylestradiol and 2mg of cyproterone acetate cause a significant suppression of gonadotropins and testosterone levels, a reduction in the number of ovarian small follicles as well as a significant reduction in AMH levels Treatment of obese PCOS women with metformin resulted in the reduction of androgens and AMH levels, without any significant decrease in follicle number On the other hand, gonadotropin-releasing hormone (GnRH) agonists do not seem to affect AMH concentrations Panidis D et al, 2010 Gynecol Endocrinol 2010. Fleming R, Fertil Steril 2005 Piltonen HumReprod 2005

Novel Role of AMH in GnRH neuron excitability AMH-dependent regulation of GnRH release could be involved in the pathophysiology of fertility and could hold therapeutic potential for treating PCOS. Irene Cimino, Nature Communications, Jan 2016

Future Directions Standard cut off level for AMH level for diagnosing PCOS needs to be established Threshold for PCOS diagnosis may need to be modified through the life span Studies with large sample size for use of AMH levels to diagnose PCOS in adolescents

Thank You!

Finally, the 2013 Endocrine Society guidelines do not include a recommendation for using AMH measurement as a routine diagnostic tool for PCOS.3 Although AMH level and oligoanovulation are correlated, AMH has not been proven to be an acceptable indicator of ovulatory dysfunction or hyper andro - genism.23 Hence, AMH level, if used, should be combined with other laboratory or clinical measures of hyperandrogenism and/or ovulatory dysfunction to maximize its diagnostic sensitivity and specificity. Furthermore, the role of AMH is unclear in diagnosing subtypes of PCOS,